Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cibus (CBUS)
NASDAQ:CBUS
Holding CBUS?
Track your performance easily
Earnings Data
Report Date
Mar 20, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.74Last Year’s EPS
-$12.59Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: -36.36%
|Next Earnings Date:Mar 20, 2025
Earnings Call Sentiment|Neutral
The earnings call revealed significant progress in Cibus's transformation to a commercial gene editing company, with successful trait developments and strategic collaborations. However, financial challenges persist with increased net losses, and there are ongoing regulatory and commercialization hurdles.Company Guidance
During the Cibus Q3 2024 earnings call, the company provided significant guidance on its ongoing transformation and strategic milestones. It has successfully completed its trait machine process, reducing the trait development cycle to 12 months from edit to greenhouse results, as demonstrated by the HT-2 trait in canola. The company highlighted its three cornerstone strategies: completing its trait machine process, operationalizing the platform to develop a multi-trait pipeline, and collaborating with major seed companies to commercialize these traits in their seeds for trade fees or royalties. Cibus has established key collaborations in rice, canola, and soybean platforms, with expectations of commercial launches for its herbicide-resistant traits in rice by 2027/2028 and canola by 2026. Financially, Cibus reduced its R&D and SG&A expenses year-over-year, with the latter decreasing to $7.7 million, and aims to cut monthly cash usage by 20% through cost-saving initiatives. However, the company recorded a net loss of $201.5 million, largely due to a goodwill impairment, with cash reserves projected to fund operations into Q1 2025.Transformation to Commercial Gene Editing Company
Cibus has evolved from an R&D-focused company to the first commercial stage gene editing company, with significant progress in product launches and trait development.
Successful Trait Development and Pipeline Expansion
Cibus completed successful field trials and greenhouse results within 12 months for multiple traits, including HT-2 in canola and herbicide-tolerant traits in rice.
Major Collaborations with Seed Companies
Cibus has established collaborations with major seed companies in each crop platform, receiving elite germplasm for trait development aimed at commercialization.
Positive Financial Adjustments
Cibus has reduced R&D expenses by $4.5 million due to strategic realignment and cost-saving initiatives, decreasing monthly cash usage by approximately 20%.
---
CBUS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CBUS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $4.40 | $5.28 | +20.00% |
| Aug 08, 2024 | $7.46 | $7.02 | -5.90% |
| May 09, 2024 | $17.85 | $17.74 | -0.62% |
| Mar 21, 2024 | $18.68 | $20.38 | +9.10% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Cibus (CBUS) report earnings?
Cibus (CBUS) is schdueled to report earning on Mar 20, 2025, TBA Not Confirmed.
What is Cibus (CBUS) earnings time?
Cibus (CBUS) earnings time is at Mar 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CBUS EPS forecast?
CBUS EPS forecast for the fiscal quarter 2024 (Q4) is -$0.74.
---